This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Ag+ + BH4− + 3 H2O → Ag0 +B(OH)3 +3.5 H2 The reduced metal atoms will form nanoparticle nuclei. Overall, this process is similar to the above reduction method using citrate. The benefit of using sodium borohydride is increased monodispersity of the final particle population. The reason for the increased monodispersity when using NaBH4 is that it is a stronger reducing agent than citrate. The impact of reducing agent strength can be seen by inspecting a LaMer diagram which describes the nucleation and growth of nanoparticles. When silver nitrate (AgNO3) is reduced by a weak reducing agent like citrate, the reduction rate is lower which means that new nuclei are forming and old nuclei are growing concurrently. This is the reason that the citrate reaction has low monodispersity. Because NaBH4 is a much stronger reducing agent, the concentration of silver nitrate is reduced rapidly which shortens the time during which new nuclei form and grow concurrently yielding a monodispersed population of silver nanoparticles. Particles formed by reduction must have their surfaces stabilized to prevent undesirable particle agglomeration (when multiple particles bond together), growth, or coarsening. The driving force for these phenomena is the minimization of surface energy (nanoparticles have a large surface to volume ratio).
In January 1821, in expectation of the abolition in Spain of the Constitution of 1812, Iturbide was chosen and was sent by the officials of New Spain with Guerrero, the leader of the rebellions. He began so-called "peace" negotiations, suggesting the parties unite to establish an independent New Spain. Later, Iturbide was dethroned and quietly captured to be executed. The simple terms that Iturbide proposed became the basis of the Plan of Iguala: the independence of New Spain (now to be called the Mexican Empire) with Ferdinand VII or another Bourbon as emperor; the retention of the Catholic Church as the official state religion and the protection of its existing privileges; and the equality of all New Spaniards, whether immigrants or native-born. Many of that laws was abolished decades later or are in present-day Mexico. The following month the other important guerrilla leader, Guadalupe Victoria, joined the alliance, and on 1 March Iturbide was proclaimed head of a new Army of the Three Guarantees. The representative of the new Spanish government, Superior Political Chief Juan O'Donojú, who replaced the previous viceroys, arrived in Veracruz on 1 July 1821, but he found that royalists held the entire country except for Veracruz, Mexico City and Acapulco. Since at the time that O'Donojú had left Spain, the Cortes was considering greatly expanding the autonomy of the overseas Spanish possessions, O'Donojú proposed to negotiate a treaty with Iturbide on the terms of the Plan of Iguala.
The most commonly reported adverse effects for I.V. formulations of acetylcysteine are rash, urticaria, and itchiness. Adverse effects for inhalational formulations of acetylcysteine include nausea, vomiting, stomatitis, fever, rhinorrhea, drowsiness, clamminess, chest tightness, and bronchoconstriction. Although infrequent, bronchospasm has been reported to occur unpredictably in some patients. Adverse effects for oral formulations of acetylcysteine have been reported to include nausea, vomiting, rash, and fever. Large doses in a mouse model showed that acetylcysteine could potentially cause damage to the heart and lungs. They found that acetylcysteine was metabolized to S-nitroso-N-acetylcysteine (SNOAC), which increased blood pressure in the lungs and right ventricle of the heart (pulmonary artery hypertension) in mice treated with acetylcysteine. The effect was similar to that observed following a 3-week exposure to an oxygen-deprived environment (chronic hypoxia). The authors also found that SNOAC induced a hypoxia-like response in the expression of several important genes both in vitro and in vivo. The implications of these findings for long-term treatment with acetylcysteine have not yet been investigated. The dose used by Palmer and colleagues was dramatically higher than that used in humans, the equivalent of about 20 grams per day. In humans, much lower dosages (600 mg per day) have been observed to counteract some age-related decline in the hypoxic ventilatory response as tested by inducing prolonged hypoxia.
Legumin is a conjugated protein with six subunits. The individual subunits have a hydrophilic α chain that is initially linked to the smaller hydrophobic β chain with a peptide bond. Both the α and β chains are encoded by the same gene. Each of the six subunits has a mass of ~50-60 kDa. During translation of the α and β chains, the polypeptide is inserted into the endoplasmic reticulum (ER) where the signal peptide that initiated the cell to translocate the chains is cleaved. A disulfide bridge is formed between the α and β chains to form prolegumin, a protein precursor. Three of these subunits come together to form a trimer in the ER. The trimer of prolegumins can be transported to the vacuole for further post-translational modification. In the vacuole, the peptide bond formed between the α and β chains is cleaved now that the disulfide bridge holds the two chains together. The cleavage of the α and β chains within the trimers signals protein maturation where two trimers to come together and form the final hexameric legumin protein.
Sources: en.wikipedia.org
Professor of Chemistry and Biochemistry at the University of Colorado at Boulder, whose research is focussed on understanding the mechanisms of cell signalling, with a speciality in phosphorylation and cancers. Member Natl. Acad. Sci. USA.
Bukele's first presidential inauguration was held on 1 June 2019. He became the 43rd president of El Salvador as well as the country's youngest president at the age of 37. Bukele held the inauguration ceremony at the National Palace due to its location in Gerardo Barrios Plaza (renovated by Bukele as mayor of San Salvador) instead of in the Blue Room (meeting room) of the Legislative Assembly in an effort to portray his presidency as focusing on the people. Bukele's supporters booed and jeered at the Legislative Assembly deputies as they were introduced. He announced a sixteen-person cabinet composed of eight men and eight women. Bukele's second presidential inauguration was held on 1 June 2024, again at the National Palace. During the inauguration, the Armed Forces of El Salvador (FAES) staged a military parade as a show of force and Bukele wore a Napoleonic-cut jacket with gold trim to evoke the image of Venezuelan liberator Simón Bolívar. He described his second inauguration as "the most important moment in our recent history" ("el momento más importante de nuestra historia reciente").
== Cellular distribution == Since 5-HEDH has not been defined biochemically or genetically, studies on its distribution have been limited to examining the ability of cells or cell microsomes to make 5-oxo-ETE from 5(S)-HETE. A wide variety of cell types possess this activity including blood neutrophils, monocytes, eosinophils, B lymphocytes, and platelets; airway epithelial cells, airway smooth muscle cells, vascular endothelial cells, and monocytes differentiated in vitro to dendritic cells; and cancer cell lines derived from many of these cells or from prostate, breast, and colon cancer cells.
The American Society for Biochemistry and Molecular Biology publishes three research journals and a monthly magazine covering society news and activity updates. ASBMB journals are peer-reviewed and cover research in the fields of microbiology, molecular genetics, RNA-related research, proteomics, genomics, transcription, peptides, cell signaling, lipidomics, and systems biology. All articles are published online as "Papers in Press" upon acceptance. As of January 2021, all three ASBMB journals are fully open access.
Naturally occurring europium (63Eu) is composed of two isotopes, 151Eu and 153Eu, with 153Eu being the more abundant (52.2% natural abundance). While 153Eu is observationally stable, 151Eu was found in 2007 to be unstable and undergo alpha decay; its measured half-life of 4.6 × 1018 years corresponds to 1 alpha decay per two minutes per kilogram of natural europium, so for practical purposes it can be considered stable. Besides the natural radioisotope 151Eu, artificial radioisotopes from 130Eu to 170Eu have been made, with the most stable being 150Eu with a half-life of 36.9 years, 152Eu with a half-life of 13.517 years, 154Eu with a half-life of 8.592 years, and 155Eu with a half-life of 4.742 years. All the others have half-lives shorter than 100 days, with the majority shorter than 3 minutes. This element also has 27 metastable isomers, with the most stable being 150mEu (12.8 hours), 152m1Eu (9.3116 hours) and 152m5Eu (96 minutes). The primary decay mode for isotopes lighter than 153Eu is electron capture to samarium isotopes, and the primary mode for heavier isotopes is beta minus decay to gadolinium isotopes. 152Eu and 154Eu can decay either way, as can 150mEu (meta state only).
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.